Abstract
Purpose
To evaluate the outcome of robotic CyberKnife (Accuray Inc. Sunnyvale, USA)-based stereotactic radiotherapy (CBK-SRT) for oligometastic cancer patients.
Patients and methods
Between May 2007 and December 2009, 95 patients with a total of 118 lesions underwent CBK-SRT (median dose 24 Gy in 3 fractions). Inclusion criteria: adult patients with limited volume cancer; suitability for SRT but not for other local therapies. Primary diagnoses included breast, lung, head and neck, gastrointestinal and other malignancies. Prostate cancer patients were excluded. Concomitant systemic therapy was given in 40 % of cases and median follow-up was 12 months. Toxicity and tumor response were evaluated using the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer (RTOG/EORTC) Scale and Response Evaluation Criteria in Solid Tumors RECIST.
Results
Toxicity was rare and observed mainly in patients with comorbidities or uncontrolled cancer. Out of 87 evaluable lesions, complete radiological response, partial response, stabilization and progressive disease were observed in 15 (17 %), 25 (29 %), 34 (39 %) and 13 (15 %) lesions, respectively. Upon restricting the analysis to lesions treated with CBK-SRT alone (no concomitant therapy), response- and local control (LC) rates remained similar. Actuarial 3-year in-field progression-free survival- (i.e. LC), progression-free survival- (PFS) and overall-survival (OS) rates were 67.6, 18.4, and 31.2 %, respectively. LC was reduced in cases of early recurrence. OS- and cause-specific survival (CSS) rates were significantly lower in patients treated for visceral lesions. Failures were predominantly out-field.
Conclusion
CBK-SRT is a feasible therapeutic approach for oligometastastic cancer patients that provides long-term in-field tumor control with a low toxicity profile. Further investigations should focus on dose escalation and optimization of the combination with systemic therapies.
Zusammenfassung
Hintergrund und Ziel
Das Ziel dieser Arbeit ist die Beurteilung der robotischen, stereotaktischen Strahlentherapie mit dem Cyberknife-System (CBK-SRT; Accuray Inc. Sunnyvale, US) für die Behandlung oligometastatischer Krebspatienten.
Patienten und Methoden
Zwischen Mai 2007 und Dezember 2009 wurden 95 Patienten (insgesamt 118 Läsionen) mit CBK-SRT (Medianwert 24 Gy in 3 Fraktionen) behandelt. Primärdiagnosen waren Brustkrebs, Lungenkrebs, Kopf- und Halskrebs, Magen-Darm-Krebs und andere bösartige Tumoren. Eine begleitende systemische Therapie wurde bei 40 % der Patienten durchgeführt. Der mittlere Nachbeobachtungszeitraum betrug 12 Monate. Die Toxizität und das Ansprechen des Tumors auf die Therapie wurden mit der Bewertungsskala der „Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer“(RTOG/EORTC) und der „Response Evaluation Criteria in Solid Tumors“ (RECIST) beurteilt.
Ergebnisse
Eine schwache Toxizität wurde besonders in Patienten mit Komorbiditäten oder unkontrolliertem Krebswachstum beobachtet. Unter 87 auswertbaren Läsionen wurde ein komplettes radiologisches Ansprechen, ein teilweises Ansprechen, eine Stabilisierung und ein Fortschreiten der Erkrankung in jeweils 15 (17 %), 25 (29 %), 34 (39 %) und 13 Läsionen (15 %) beobachtet. Wenn die Analyse auf mit CBK-SRT behandelte Läsionen (keine begleitende Therapie) beschränkt wurde, wurden ähnliche Ansprechraten und lokale Tumorkontrolle ausgewertet. Das 3-jährige, lokale progressionsfreie Überleben (LC, lokale Kontrolle), das progressionsfreie Überleben (PFS) und das allgemeine Überleben (OS) lagen jeweils bei 67,6%, 18,4% und 31,2 %. Im Falle der frühen Rezidive war die LC niedriger. Deutlich niedrigere OS und ursachenspezifische Überlebensraten (CSS) wurden in Patienten mit Magen-Darm-Krebs beobachtet. Das Therapieversagen war hauptsächlich außerhalb des Strahlenfelds.
Schlussfolgerung
Der therapeutische Ansatz mit CBK-SRT funktioniert grundsätzlich für Patienten mit oligometastatischem Krebs. Es wirkt eine lange andauernde Tumorkontrolle innerhalb des Strahlenfelds mit weniger Toxizität. Weitere Untersuchungen zur Dosissteigerung und Optimierung der Kombination mit systemischer Therapie sollten durchgeführt werden.
References
Benedict SH, Lin PS, Zwicker RD et al (1997) The biological effectiveness of intermittent irradiation as a function of overall treatment time: development of correction factors for linac based stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 37:765–769
Cheng YC, Ueno NT (2012) Improvement of survival and prospect of cure in patients with metastatic breast cancer. Breast Cancer 19:191–199
Chua TC, Liauw W, Chu F, Morris DL (2012) Viewing metastatic colorectal cancer as curable chronic disease. Am J Clin Oncol 35:77–80
Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346
D’Agostino GR, Autorino R, Pompucci A et al (2011) Whole-brain radiotherapy combined with surgery or stereotactic radiotherapy in patients with brain oligometastases: long-term analysis. Strahlenther Onkol 187:421–425
Dahele M, Senan S (2011) The role of stereotactic ablative radiotherapy for early-stage and oligometastatic non-small cell lung cancer: evidence for changing paradigms. Cancer Res Treat 43:75–82
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
Fokas E, Henzel M, Engenhart-Cabillic R (2010) A comparison of radiotherapy with radiotherapy plus surgery for brain metastases from urinary bladder cancer: analysis of 62 patients. Strahlenther Onkol 186:565–571 (Erratum in: Strahlenther Onkol 2011;187:267)
Fowler JF, Welsh JS, Howard SP (2004) Loss of biological effect in prolonged fraction delivery. Int J Radiat Oncol Biol Phys 159:242–249
Geiger S, Cnossen JA, Horster S et al (2011) Long-term follow-up of patients with metastatic breast cancer: results of a retrospective, single-center analysis from 2000–2005. Anticancer Drugs 22:933–939
Gill B, Oermann E, Ju A et al (2012) Fiducial-free CyberKnife stereotactic body radiation therapy (SBRT) for single vertebral body metastases: acceptable local control and normal tissue tolerance with 5 fraction approach. Front Oncol 2:39
Halley ML, Gerszten PC, Heron DE et al (2011) Efficacy and cost-effectiveness analysis of external beam and stereotactic body radiation therapy in the treatment of spine metastases: a matched-pair analysis. J Neurosurg Spine 14:537–542
Jabbour SK, Daroui P, Moore D et al (2011) A novel paradigm in the treatment of oligometastatic non-small cell lung cancer. J Thorac Dis 3:4–9
Jereczek-Fossa BA, Beltramo G, Fariselli L et al (2012) Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastastic prostate cancer. Int J Radiat Oncol Biol Phys 82:889–897
Kaplan E, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457–481
Lee MK, Baek SK, Kim SY et al (2011) Awareness of incurable cancer status and health-related quality of life among advanced cancer patients: a prospective cohort study. Palliat Med (Epub ahead of print)
Milano MT, Katz AW, Zhang H, Okunieff P (2012) Oligometastases treated with stereotactic body radiotherapy: long term follow-up of prospective study. Int J Radiat Oncol Biol Phys 83:878–886
Riboldi M, Orecchia R, Baroni G (2012) Real-time tumour tracking in particle therapy: technological developments and future perspectives. Lancet Oncol 13:e383–e391
Ricardi U, Filippi AR, Guarneri A et al (2012) Stereotactic body radiation therapy for lung metastases. Lung Cancer 75:77–81
Salama JK, Hasselle MD, Chmura SJ et al (2012) Stereotactic body radiotherapy for multisite extracranial metastases. Cancer 118:2962–2970
Thariat J, Li G, Angellier G et al (2009) Current indications and ongoing clinical trials with CyberKnife stereotactic radiotherapy in France in 2009. Bull Cancer 96:853–864 (article in French)
Torshabi AE, Pella A, Riboldi M, Baroni G (2010) Targeting accuracy in real-time tumor tracking via external surrogates: a comparative study. Technol Cancer Res Treat 9:551–562
Vavassori A, Jereczek-Fossa BA, Beltramo G et al (2010) Image-guided robotic radiosurgery as salvage therapy for locally recurrent prostate cancer after external beam irradiation: retrospective feasibility study on six cases. Tumori 96:71–75
Voigtmann K, Köllner V, Einsle F et al (2010) Emotional state of patients in radiotherapy and how they deal with their disorder. Strahlenther Onkol 186:229–235
Wiechselbaum RR, Hellman S (2011) Oligometastases revisited. Nat Rev Clin Oncol 8:378–382
Wiggenraad R, Verbeek-de Kanter A, Mast M et al (2012) Local progression and pseudo progression after single fraction or fractionated stereotactic radiotherapy for large brain metastases: a single centre study. Strahlenther Onkol 188:696–701
Wilhelm M (2012) Impaired cognitive function and structural changes in cerebral white matter after chemotherapy. Strahlenther Onkol 188:525–526 (article in German)
Xie Y, Djajaputra D, King CR et al (2008) Intrafractional motion of the prostate during hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys 72:236–246
Zabel-du Bois A, Milker-Zabel S, Henzel M et al (2012) Evaluation of time, attendance of medical staff, and resources during stereotactic radiotherapy/radiosurgery: QUIRO-DEGRO Trial. Strahlenther Onkol (Epub ahead of print)
Conflict of interest
On behalf of all authors, the corresponding author states that there are no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jereczek-Fossa, B., Bossi-Zanetti, I., Mauro, R. et al. CyberKnife robotic image-guided stereotactic radiotherapy for oligometastic cancer. Strahlenther Onkol 189, 448–455 (2013). https://doi.org/10.1007/s00066-013-0345-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00066-013-0345-y